9.35
-0.05(-0.53%)
Currency In USD
| Previous Close | 9.4 |
| Open | 9.4 |
| Day High | 9.48 |
| Day Low | 9.24 |
| 52-Week High | 14.44 |
| 52-Week Low | 4.93 |
| Volume | 623,757 |
| Average Volume | 1.01M |
| Market Cap | 803.11M |
| PE | -16.4 |
| EPS | -0.57 |
| Moving Average 50 Days | 10.51 |
| Moving Average 200 Days | 9.39 |
| Change | -0.05 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $1,693.84 as of September 09, 2025 at a share price of $9.35. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $2,291.67 as of September 09, 2025 at a share price of $9.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
GlobeNewswire Inc.
28 minutes ago
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging prof
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
GlobeNewswire Inc.
Sep 02, 2025 11:30 AM GMT
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
GlobeNewswire Inc.
Aug 26, 2025 11:30 AM GMT
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,